Daxdilimab for Alopecia Areata
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests Daxdilimab, an injectable medication, in people with significant hair loss from Alopecia Areata. The goal is to see if it can safely reduce hair loss by changing how the immune system reacts.
Will I have to stop taking my current medications?
The trial requires that you stop using certain medications that might affect hair regrowth, such as steroids, minoxidil, and some topical treatments, at least 4 weeks before starting the trial. Other medications like biologics or immunosuppressants need to be stopped 8 weeks or more before the trial, depending on the specific drug.
Is Daxdilimab safe for humans?
How is the drug Daxdilimab different from other treatments for alopecia areata?
What evidence supports the effectiveness of the drug Daxdilimab for treating alopecia areata?
Research shows that drugs targeting the JAK pathway, like Daxdilimab, can help with hair regrowth in alopecia areata by reducing inflammation and altering immune responses. Similar drugs, such as baricitinib, have shown consistent benefits in clinical trials for severe cases of this condition.89111213
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with moderate-to-severe alopecia areata, having experienced significant hair loss (50-95%) without regrowth for the past 6 months to less than 7 years. Participants must be willing to maintain their current hairstyle and color throughout the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daxdilimab administered subcutaneously over 32 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Daxdilimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London
Horizon Therapeutics Ireland DAC
Lead Sponsor